tbuckley/cabot-search huggingface dataset:
AB0783 A PRECLINICAL STUDY FOCUSSING ON OXIDATIVE STRESS IN ADJUVANT ARTHRITIS RAT MODEL TO EVALUATE THE EFFECT OF VARIOUS MOLECULAR WEIGHTS OF HYALURONIC ACID IN MONOTHERAPY AND IN COMBINATION WITH METHOTREXATE
Authors: S. Khademnematolahi, K. Bauerova, K. Pružinská, F. Drafi, S. Ponist, K. Švík, J. Muchova
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Hyaluronic acid (HA) has been shown in recent research to have chondroprotective and anti-inflammatory effects in rheumatoid arthritis. <h3>Objectives:</h3> The purpose of this study was to examine HA and its combination with methotrexate (MTX) in rats suffering from adjuvant arthritis (AA). <h3>Methods:</h3> In our studies, we used male Lewis rats and the arthritis was induced by intradermal injection of 0.1 mL suspension of heat-killed <i>Mycobacterium butyricum</i> mixed with incomplete Freund's adjuvants at a dosage of 12 mg/mL into the base of a tail of Lewis rats (1,2). These groups of animals were included in the experiment: healthy controls, animals with arthritis who were not treated, animals with arthritis who received treatment with HA and MTX, and animals with arthritis who received treatment with HA and MTX combined. Animals received daily doses of 0.5 mg and 5 mg/kg b.w. of HA of varying molecular weights (0.43, 0.99, and 1.73 MDa) alone or combined with methotrexate in an oral dose of 0.3 mg/kg b.w. twice weekly. <h3>Results:</h3> We measured improving effect of HA on antioxidant enzymes in erythrocytes (superoxide dismutase and glutathione peroxidase) and on plasma antioxidant capacity. Further, we discovered that HA decreased the amount of lipid hydroperoxides in plasma, a sign of oxidative damage to lipids developing during arthritis. The effect of HA with the highest molecular weight was the most notable not only on the oxidative stress parameters, but also on inflammatory markers and the main biometric markers. <h3>Conclusion:</h3> HA and MTX therapy together prevented the development of arthritis in rats more successfully than MTX alone. There is a possibility that this finding will lead to improved treatments for rheumatoid arthritis patients after its clinical implementation. <h3>REFERENCES:</h3> [1] Bauerova, Katarina, et al.. The role of endogenous antioxidants in the treatment of experimental arthritis. In Antioxidants 2019 Apr 6. IntechOpen [2] Chrastina, Martin - Drafi, František - Pružinska, Katarina - Poništ, Silvester - Kamga, Kevine Silihe - Khademnematolahi, Sasan et al 2023. Crocus sativus L. Extract (Saffron) Effectively Reduces Arthritic and Inflammatory Parameters in Monotherapy and in Combination with Methotrexate in Adjuvant Arthritis. Nutrients 15(2023): 4108. <b>Table 1.</b> <h3>Acknowledgements:</h3> Projects APVV-15-0308 and VEGA 2/0136/20. Czech company Contipro has deliver all hyaluronic compounds for this experiment. <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0651 MANAGEMENT OF ARTHRALGIA SUSPICIOUS OF PROGRESSING TO RHEUMATOID ARTHRITIS: A MOROCCAN RHEUMATOLOGIST’S SURVEY
Authors: C. Charoui, B. Amine, S. Rostom, S. Zemrani, H. EL-Kasmi, I. EL Binoune, R. Bahiri
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Nowadays, Rheumatoid Arthritis (RA) patients are treated earlier, even before the diagnosis fulfills the classification criteria. Avoiding the onset of RA by dint of managing earlier the patients at risk of developing RA is a focus of multiple recent researches. Therefore, effective prevention strategies may represent a considerable advance in the management of RA. <h3>Objectives:</h3> The aim of our study is to determine how Moroccan rheumatologists manage patients who present arthralgia at risk of becoming RA. <h3>Methods:</h3> It was a cross-sectional descriptive study carried out among Moroccan rheumatologists in the public and private sectors through a questionnaire established in a declarative and anonymous manner. This questionnaire was validated by an expert's committee before submitting it to rheumatologists. It consisted of 27 single or multiple-choice questions fulfilled in "Google Forms". <h3>Results:</h3> 135 Moroccan rheumatologists replied to the questionnaire. According to the physicians, the most frequent sites of arthralgia in these patients were the hands (134/135; 99.3%) and feet (56/135; 51.4%). 99.3% (134/135) of them ordered systematically an inflammatory assessment. 88.1% (119/135) requested systematically an immunological test. The most important risk factor for developing RA during short-term follow-up was a family history of chronic inflammatory rheumatism (119/135; 88.1%), followed by the MCP arthralgia (113/135; 83.7%), a morning stiffness &gt;30 min (112/135; 83%), the feet arthralgia and a history of smoking (51/135; 37.8%). 95.6% (129/135) used systematically an imagery method in the decision-making process. Ultrasound was the first choice (100/135; 74.1%), followed by conventional radiography (31/135; 23%) and magnetic resonance imaging (MRI) (4/135; 3%). If synovitis/tenosynovitis were Doppler positive, most participants (130/135; 96.3%) in the survey started Methotrexate (MTX). Only a minority preferred Leflunomide 3%. Without synovitis or tenosynovitis at US, only 11/135 (8.1%) decided to start treatment, while 87/135 (64.4%) preferred to follow up the patient. The factors that encouraged initiation of disease-modifying therapy were: positive ACPA (129/135; 95.6%), followed by the presence of a biological inflammatory syndrome (115/135 85.2%) and positive rheumatoid factor (107/135; 79.3%). <h3>Conclusion:</h3> Patients with arthralgia suspicious of progressing to rheumatoid arthritis (RA), represent a clinical and therapeutic challenge. Thus, it is important to develop recommendations for a well codified management. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> Chaimae Charoui would like to thank all co-authors: Bouchra Amine, Imane El binoune, Salma Zemrani, Hind El Kacimi, Samira Rostom, Rachid Bahiri and patients who agreed to participate in this study. <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0761 RELATIONSHIP OF TOBACCO AND ALTERED FUNCTIONAL TESTS WITH FIBROSING LUNG IN PATIENTS WITH RHEUMATOID ARTHRITIS
Authors: L. Álvarez Ortiz, P. C. Aguilera Cros, M. León Luque
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Risk factors associated with the development of interstitial lung disease (ILD) in patients with rheumatoid arthritis (RA) include: male sex (2-3 males: 1 female), advanced age, erosive and evolved RA, rheumatoid nodules, smoking (OR 3.8 for smokers &gt; 25 packs/year), and high titers of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA). Poor prognostic factors include: HRCT (high-resolution computed tomography) pattern of usual interstitial pneumonia (UIP) with altered baseline functional tests [forced vital capacity (FVC) &lt;80%, diffusion capacity (DLCO) &lt;80%]. <h3>Objectives:</h3> -To analyze different risk factors and poor prognostic factors in a cohort of patients with RA-ILD. -To evaluate the statistical association (SA) between altered respiratory functional tests (RFT: FVC&lt;80% and DLCO&lt;80%) with tobacco (smokers, former smokers and non smokers) and with HRCT patterns. -To determine the SA between tobacco with the HRCT UIP vs NON-UIP patterns and with the fibrosing patterns [progressive fibrosing UIP and fibrotic NSIP (non-specific interstitial pneumonia)]. -<b></b>To evaluate the SA of altered baseline RFT with the HRCT pattern and with mortality. <h3>Methods:</h3> Descriptive study of 60 patients seen in an ILD Clinic, collected from 01/01/2020 to 01/01/2023. Patients with a diagnosis of RA fulfilling ACR 2010 criteria were included, who also had a diagnosis of secondary ILD according to the SEPAR 2003 consensus. For its part, the ILD has been divided based on HRCT results: UIP and NON-UIP. Approved by the Ethics Committee. Quantitative variables are expressed as mean (SD) and dichotomous variables as percentages (%). The association of qualitative variables was analysed using the Chi-square test. Astatistical analysis with SPSS. <h3>Results:</h3> The general characteristics of the patients are summarized in Table 1. After analyzing our results, there was a significant SA between patients with tobacco exposure and altered baseline FVC (p=0.01). SA could not be demonstrated between tobacco and baseline DLCO (p=0.56), nor between the HRCT pattern and baseline FVC (p=0.90); as well as baseline HRCT/DLCO (p=0.76). We also found no association between tobacco and the HRCT pattern (p=0.70), as was the case with the fibrosing pattern (p=0.59). If we studied the number of deaths, we found no SA with altered RFT (p=0.34 for FVC; p=0.64 for DLCO), nor with the HRCT pattern (p=0.55). <h3>Conclusion:</h3> Our results, in general, do not coincide with those published in literature. Male sex, exposure to smoking, and fibrosing pattern represent a worse prognosis for patients with RA-ILD. However, more studies are needed to determine more precisely how these risk factors affect the disease. <h3>REFERENCES:</h3> <b>NIL.</b> <b>Table 1.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1319 RATES AND FACTORS ASSOCIATED WITH THERAPY DISCONTINUATION IN A MULTICENTER COHORT OF PATIENTS WITH GIANT CELL ARTERITIS FOLLOWED FOR 7 YEARS
Authors: M. Nitsa, C. Tsalapaki, A. Lazarini, E. Argyriou, V. Dania, K. Boki, G. Evangelatos, A. Iliopoulos, M. Pappa, P. P. Sfikakis, M. G. Tektonidou, A. Georgountzos, E. Kaltsonoudis, P. V. Voulgari, A. Drosos, E. Theotikos, C. Papagoras, T. Dimitroulas, A. Garyfallos, E. Kataxaki, G. Vosvotekas, D. Boumpas, E. Hadziyannis, D. Vassilopoulos
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> There are limited data regarding therapy discontinuation in patients with giant cell arteritis (GCA) followed for a long period of time (&gt;5 years). <h3>Objectives:</h3> We aimed to evaluate the long-term rate and factors associated with therapy discontinuation in a real-life GCA cohort. <h3>Methods:</h3> Patient and treatment data were collected at 3 different time points (baseline, 2 and 5 years later) in a multicenter, prospective GCA cohort. The rates of therapy discontinuation and its predictors were identified by uni- and multi- variable logistic regression analyses <h3>Results:</h3> 89 patients with data available for all time points of evaluation were included in the study; 75% were women with a mean age of 71.6±8.1 years and a median disease duration from diagnosis to last evaluation of 7.2 years. All patients had been treated initially with glucocorticoids (GCs, 100%, median daily dose: 40mg prednisolone) while during follow-up, 34% (30/89) had received cs-DMARDs and/or b-DMARDs (17%, 15/89), respectively. 40.4% (36/89) of patients had ≥1 disease relapses during this period. At the last follow-up visit, 48% (43/89) of patients managed to discontinue all therapies and 54% GCs (48/89), respectively. By uni-variable logistic regression analysis, factors associated with therapy discontinuation included the absence of relapses (OR=2.76; 95%CI: 1.13-6.74) and the lack of treatment with GC-sparing agents (b- and/or cs-DMARDs, OR=4.69; 95%CI: 1.76-12.50). By multi-variable logistic regression analysis, patients who did not require a GC-sparing agent (b- and/or cs-DMARDs) had a higher likelihood to discontinue all therapies (OR=5.15; 95%CI: 1.56.-17.01). <h3>Conclusion:</h3> In this real-life GCA cohort, approximately 40% of patients relapsed while only half were able to discontinue all therapies, ~7 years after diagnosis. The absence of relapses and requirement for GC-sparing agents were associated with a higher likelihood of drug discontinuation. Whether earlier introduction of GC-sparing agents could improve the chance for drug discontinuation by preventing relapses remains to be studied. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> Supported in part by the Greek Rheumatology Society and Professional Association of Rheumatologists (ERE-EPERE) and the Special Account for Research Grants (S.A.R.G.), National and Kapodistrian University of Athens, Athens, Greece (DV #12085, 12086). <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0035 EFFICACY AND SAFETY OF TOCILIZUMAB TREATMENT IN FAMILIAL MEDITERRANEAN FEVER: A SYSTEMATIC REVIEW
Authors: P. Mertz, S. Georgin-Lavialle, V. Hentgen
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Familial Mediterranean Fever (FMF), the most common monogenic autoinflammatory disease, is characterized by recurrent fever and serosal inflammation. While colchicine effectively manages most cases, approximately 5% of patients exhibit colchicine resistance, necessitating alternative therapies to control inflammation and prevent AA amyloidosis. Potential biologic treatments include IL1b, TNF alpha and IL6 inhibitors. However, challenges like cost and availability may hinder the prescription of IL1b inhibitors therapies in certain regions. Conversely, tocilizumab (TCZ), an IL6 receptor inhibitor therapy, offers a cost-effective and manageable administration regimen, particularly relevant if IL-1 inhibitors prove ineffective, although limited data on its efficacy in FMF exists. <h3>Objectives:</h3> Evaluate the efficacy and safety of tocilizumab for FMF treatment. <h3>Methods:</h3> A systematic review according to PRISMA guidelines identified 237 articles on TCZ use in FMF. After selection, 14 articles were included: 2 double-blind randomized controlled trials (RCTs), 2 retrospective studies, and 10 case reports. <h3>Results:</h3> Multicenter double-blind RCTs report mixed outcomes in FMF patients without AA amyloidosis due to study design and genetic heterogeneity. Retrospective studies suggest TCZ may be beneficial in FMF patients with established renal AA amyloidosis, preventing renal disease progression and potentially being more effective in managing disease attacks. TCZ has a safe profile, lacking specific adverse events, though data on TCZ use in pregnant or lactating patients are lacking. <h3>Conclusion:</h3> This review summarizes TCZ's current state of research, safety, and efficacy in FMF. While IL1b inhibitors remain the first choice for colchicine-resistant or intolerant cases, TCZ may be of interest in established AA amyloidosis. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0656 SUSTAINED REMISSION IN RHEUMATOID ARTHRITIS: WHAT ARE THE PREDICTIVE FACTORS?
Authors: J. Mohammed Khalil, A. Nessrine, E. M. Imane, T. Harzy
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Rheumatoid arthritis is the most common chronic inflammatory rheumatic disease. Its management is well codified, with the aim of achieving remission according to the TREAT 2 TARGET strategy. However, few data are available on the predictors of prolonged remission. <h3>Objectives:</h3> The aim of this study was to determine the prevalence and predictors of sustained remission in rheumatoid arthritis. <h3>Methods:</h3> This is a retrospective descriptive and analytical study including a sample of 139 patients followed up for rheumatoid arthritis in the rheumatology consultation of the Hassan II University Hospital in Fez. Sustained remission was defined by a disease activity score (DAS28-CRP) below 2.6 over a period of at least six months without recourse to corticosteroids. Predictive factors for sustained remission were identified by logistic regression analysis using SPSS software. <h3>Results:</h3> Of the 139 patients included in our study, the mean age was 59.88 ±13.09 years. Female to male ratio (F/M) was 4/1. 18.7% of our patients were suffering from hypertension, and 19.4% from diabetes. Regarding the characteristics of RA, it was seropositive in 78.1% (107) of patients and erosive in 89.3% (108). 92.1% were on methotrexate, 27.3% (38) on bDMARD. Sustained remission was observed in 40.3% (56) of cases. In linear regression analysis, variables associated with sustained remission were age less than 50 years with p=0.014 and OR= 3.479 (1.663-5.266) 95% CI, HAQ &lt;0.5 with p=0.043 and OR=1.857 (1.090-2.414) 95% CI, seropositive RA with p=0.039 OR = 1.256 (1.070-2.532) 95% CI. The use of Rituximab and TNF alpha(tumor necrosis factor) alpha inhibitors was also associated with sustained remission with p and OR values respectively at p=0.048 OR 4.765 (1.023-7.241) 95% CI and p=0.018 OR 4.295 (1.491-9.547) 95% CI. <h3>Conclusion:</h3> In our sample, and given the results, long term remission was achieved in 40.3% of patients. The following elements were associated with sustained remission: Age under 50, HAQ&lt;0.5, seropositive RA, patients on Rituximab and patients on TNF alpha inhibitors. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0614 EXPLORING IMMUNOLOGICAL DIFFERENCES IN SERONEGATIVE AND SEROPOSITIVE RHEUMATOID ARTHRITIS
Authors: B. C. LI, R. Su, Q. L. Guo, C. Wang
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Rheumatoid arthritis (RA) is an autoimmune disease encompassing various disease subtypes, with RA-related autoantibodies playing a role in various clinical and pathological aspects of RA. Seronegative Rheumatoid Arthritis (SnRA), characterized by its unique seronegative antibody phenotype, hinders the understanding of RA disease subtypes. <h3>Objectives:</h3> This study aims to investigate potential pathogenic mechanisms by contrasting the peripheral blood immune cell-cytokine characteristics in patients with Seronegative Rheumatoid Arthritis (SnRA) and Seropositive Rheumatoid Arthritis (SpRA), aiming to pinpoint the most notable immunological differences between the two and provide insights into their potential etiological mechanisms. <h3>Methods:</h3> This study included 41 patients with Seronegative Rheumatoid Arthritis (SnRA) and 79 patients with Seropositive Rheumatoid Arthritis (SpRA). Patients were randomly divided into a modeling group and a validation group in an 8:2 ratio using a random number table. General clinical data were collected, and flow cytometry was employed to examine peripheral blood lymphocyte subsets and CD4+ T cell subsets. Additionally, CBA was utilized to measure serum cytokine levels. Clinical and immunological differences between the two groups were analyzed and sequentially screened using a combination of univariate logistic regression and random forest methods. <h3>Results:</h3> (1) Univariate logistic regression identified differential indicators between SnRA and SpRA, including white blood cell count, T lymphocyte count, and CD8+ T cell count, among others (P &lt; 0.05) (Figure 1); (2) Random forest analysis prioritized the importance of the aforementioned differential indicators. Based on the sorted results, a stepwise random forest regression analysis was conducted, revealing the lowest out-of-bag error estimation rate when the variable number was 3 (Figure 2A) (Figure 2B); (3) ROC curves were generated for the key differential indicators, serum IL-4, TNF-α, and IL-2, demonstrating good discriminatory ability for each in the population (Figure 2C). <h3>Conclusion:</h3> Levels of IL-4, TNF-α, and IL-2 emerge as pivotal immunological differential indicators between SnRA and SpRA, potentially serving as triggering mechanisms for the differential production of autoantibodies in patients with SnRA and SpRA. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0106 INTRA- VERSUS EXTRACELLULAR SYNOVIAL FLUID CALCIUM PYROPHOSPHATE CRYSTALS FOR THE DIAGNOSIS OF ACUTE CALCIUM PYROPHOSPHATE CRYSTAL ARTHRITIS
Authors: D. Harris, D. White, U. Arad
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Acute calcium pyrophosphate (CPP) crystal arthritis is characterised by the presence of CPP crystals in the synovial fluid of a clinically inflamed joint. CPP crystals can be found in an intracellular or extracellular location; however, no studies have specifically assessed the importance of the CPP crystal location in the clinical setting. <h3>Objectives:</h3> The objective of this retrospective cohort study was to assess the relevance of the CPP crystal location (intra vs. extracellular) in the diagnostic work up of acute CPP crystal arthritis. <h3>Methods:</h3> Data was collected from Waikato District Health Board (WDHB) to identify a study population with synovial fluid samples positive for CPP crystals. The cohort was divided into two groups, one with intracellular and one with extracellular CPP crystals. The proportion of cases diagnosed with acute CPP crystal arthritis according to predefined criteria, were compared between these cohorts. Further analysis was made with respect to demographics, other laboratory results and cartilage calcification. <h3>Results:</h3> The study population consisted of 134 patients, 108 with intracellular CPP crystals and 26 with extracellular CPP crystals. Acute CPP crystal arthritis cases made up 84% of the intracellular cohort and 42% of the extracellular cohort (p&lt;0.001). When septic arthritis cases were excluded from the analysis, 96% of cases with intracellular CPP crystals were secondary to acute CPP crystal arthritis (p&lt;0.001). <h3>Conclusion:</h3> Our study suggests the presence of an intracellular CPP crystal location is more likely to be associated with acute CPP crystal arthritis. An extracellular CPP crystal location appears less specific and more likely to be an incidental finding. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>